Delafloxacin
Brand names: Quofenix
Delafloxacin is a fluoroquinolone antibacterial used for acute bacterial skin and skin-structure infections and certain community-acquired pneumonias.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits the bacterial enzymes DNA gyrase and topoisomerase IV, blocking DNA replication and transcription and leading to bacterial cell death.
Prescribing in practice
- Fluoroquinolones carry a risk of disabling and potentially long-lasting or irreversible adverse effects on tendons, muscles, joints, and the nervous system, so MHRA advises restricting use to situations where other antibacterials are unsuitable.
- Tendon rupture and aortic aneurysm or dissection have been associated with fluoroquinolones, with greater risk in older patients and those on corticosteroids.
- They may prolong the QT interval and can cause central nervous system effects including seizures.
Monitoring
Monitor for tendon, musculoskeletal, neurological, and psychiatric adverse effects, and stop treatment at the first sign of a serious reaction.
Counselling the patient
- Stop the medicine and seek advice immediately if you develop tendon pain or swelling, or new neurological or psychiatric symptoms.
- Avoid taking indigestion remedies, or iron and other mineral supplements, around the same time as the dose.
Evidence & guidelines
MHRA safety guidance on systemic fluoroquinolones underpins the restricted-use recommendation, with efficacy demonstrated in randomised trials for skin and respiratory infections.
Reference: MHRA Drug Safety Update; BSAC; UKHSA AMR; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
- PID Severity (CDC Diagnostic Criteria) · Gynaecological Infections
- Gustilo-Anderson Classification (Open Fractures) · Fracture Classification
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023